Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall

2

By Michael Erman and Julie Steenhuysen Oct 22 (Reuters) – Moderna and Merck said on Thursday that their mRNA cancer vaccine when combined with Merck's widely used immunotherapy cut the risk of

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)